Entrada Therapeutics (NASDAQ:TRDA) Director Bernhardt Zeiher Buys 5,000 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Bernhardt Zeiher bought 5,000 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average cost of $5.86 per share, for a total transaction of $29,300.00. Following the completion of the purchase, the director directly owned 5,000 shares of the company’s stock, valued at $29,300. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Entrada Therapeutics Price Performance

Shares of Entrada Therapeutics stock opened at $6.31 on Friday. Entrada Therapeutics, Inc. has a 1 year low of $4.93 and a 1 year high of $16.45. The firm has a market cap of $244.96 million, a PE ratio of -1.58 and a beta of -0.09. The company has a 50 day simple moving average of $11.67 and a two-hundred day simple moving average of $10.88.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.95) EPS for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.11. Entrada Therapeutics had a negative net margin of 2,895.05% and a negative return on equity of 51.22%. The firm had revenue of $0.88 million for the quarter, compared to analyst estimates of $2.92 million. As a group, research analysts anticipate that Entrada Therapeutics, Inc. will post -4.12 earnings per share for the current year.

Institutional Investors Weigh In On Entrada Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC increased its stake in Entrada Therapeutics by 9.8% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock worth $176,000 after purchasing an additional 1,560 shares during the period. Alliancebernstein L.P. boosted its stake in shares of Entrada Therapeutics by 7.1% during the third quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock valued at $141,000 after purchasing an additional 1,620 shares during the period. Great Lakes Advisors LLC boosted its stake in shares of Entrada Therapeutics by 5.5% during the fourth quarter. Great Lakes Advisors LLC now owns 43,268 shares of the company’s stock valued at $445,000 after purchasing an additional 2,239 shares during the period. Quadrature Capital Ltd boosted its stake in shares of Entrada Therapeutics by 13.5% during the fourth quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock valued at $209,000 after purchasing an additional 2,424 shares during the period. Finally, First Trust Advisors LP grew its holdings in shares of Entrada Therapeutics by 3.6% in the second quarter. First Trust Advisors LP now owns 75,120 shares of the company’s stock worth $505,000 after purchasing an additional 2,631 shares during the last quarter. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Guggenheim raised Entrada Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 11th. Roth Mkm set a $10.00 price objective on Entrada Therapeutics in a research report on Friday, May 8th. Cantor Fitzgerald initiated coverage on Entrada Therapeutics in a report on Wednesday, April 1st. They set an “overweight” rating on the stock. HC Wainwright downgraded Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Entrada Therapeutics in a research note on Friday, March 27th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $18.25.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.